SC 112

Drug Profile

SC 112

Alternative Names: IBAT inhibitor - Pharmacia

Latest Information Update: 27 Oct 2000

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Antihyperlipidaemics; Small molecules
  • Mechanism of Action Sodium-bile acid cotransporter-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hypercholesterolaemia

Most Recent Events

  • 27 Oct 2000 No-Development-Reported for Hypercholesterolaemia in USA (Unknown route)
  • 05 Apr 2000 Monsanto has merged with Pharmacia & Upjohn to form Pharmacia Corporation
  • 14 Sep 1998 Preclinical development for Hypercholesterolaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top